Stallergenes Greer Announces Its 2016 Financial Calendar

LONDON--()--Regulatory News:

Stallergenes Greer plc (the “Company”) (Paris:STAGR) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced its financial calendar for the year 2016:

FY 2015 Results   27th April 2016
Investor and Analyst Call   28th April 2016
Annual Report Filing   29th April 2016
Annual General Meeting   9th June 2016
1st semester 2016 Results   25th August 2016
Strategy and R&D Day   November 2016

Please note that Stallergenes Greer will release its financial results for the year 2015 the 27th of April after market close. Fereydoun Firouz, Chief Executive Officer, and Peter Bühler, Chief Financial Officer, will host the investor and analyst call on the 28th of April at 2:00 pm (CET).

The Company’s Annual General Meeting will be held on the 9th of June in Paris, France. Stallergenes Greer will hold a Strategy and R&D Day in Antony, France in November 2016.

ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification: 4577

Market: Euronext Paris regulated market

Additional information is available at http://www.stallergenesgreer.com

This document (including information incorporated by reference in this document), oral statements made and other information published by the company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe", "expects", "project", "estimated", "forecast", "should", "plan", "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in our prospectus filed with the French Autorité des marchés financiers on September 3, 2015. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.

Contacts

Investor and analyst relations
Peter Bühler, +33 1 55 59 23 22
Chief Financial Officer
investorrelations@aresallergyco.com
or
Investor relations agency
FTI Consulting
Arnaud de Cheffontaines, +33 1 47 03 69 48
arnaud.decheffontaines@fticonsulting.com
or
Media relations
Lise Lemonnier, + 33 1 55 59 20 96
Head of Global Communications
llemonnier@stallergenes.com

Contacts

Investor and analyst relations
Peter Bühler, +33 1 55 59 23 22
Chief Financial Officer
investorrelations@aresallergyco.com
or
Investor relations agency
FTI Consulting
Arnaud de Cheffontaines, +33 1 47 03 69 48
arnaud.decheffontaines@fticonsulting.com
or
Media relations
Lise Lemonnier, + 33 1 55 59 20 96
Head of Global Communications
llemonnier@stallergenes.com